Kawasaki disease following immunization reported to the Canadian Immunization Monitoring Program ACTive (IMPACT) from 2013 to 2018

Khaled Alsager; Nirma Khatri Vadlamudi; Taj Jadavji; Julie A. Bettinger; Cora Constantinescu; Wendry Vaudry; Ben Tan; Laura Sauvé; Manish Sadarangani; Scott A. Halperin; Karina A. Top

doi:10.1080/21645515.2022.2088215

Kawasaki disease following immunization reported to the Canadian Immunization Monitoring Program ACTive (IMPACT) from 2013 to 2018

Khaled Alsager, Nirma Khatri Vadlamudi, Taj Jadavji, Julie A. Bettinger, Cora Constantinescu, Wendry Vaudry, Ben Tan, Laura Sauvé, Manish Sadarangani, Scott A. Halperin, Karina A. Top

Medicine

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

5 Citas (Scopus)

Resumen

Kawasaki disease (KD) is an acute systemic vasculitis primarily affecting children younger than 5 y of age that has been reported as an adverse event following immunization (AEFI). The Canadian Immunization Monitoring Program ACTive (IMPACT) conducts active surveillance for KD following immunization across Canada. We characterized KD cases reported to IMPACT between 2013 and 2018. Cases admitted to an IMPACT hospital with a physician diagnosis of complete or incomplete KD with onset 0–42 d following vaccination were reviewed. Cases meeting the Brighton Collaboration case definition (BCCD) levels of diagnostic certainty levels 1 a/b, 2a/b or 3a-e were defined as KD cases. Demographic and vaccination characteristics were compared between KD cases and non-cases. Of 84 cases reviewed, 58 met the BCCD: 47 (81%) cases met level 1a (Complete KD), 8 (14%) met level 1b (Incomplete KD), 2 (3%) met level 2a, and 1 (2%) met level 2c (Probable KD). Median age at admission was 13 months (interquartile range 7–26 months). A median of 9.5 cases were reported per year (range 4–14). Thirty-one (53%) KD cases were temporally associated with diphtheria-tetanus acellular pertussis containing vaccinations, followed by 21 (36%) cases with pneumococcal conjugate vaccines. Symptom onset was 0–14 d after vaccination in 32 (55%) cases. Echocardiogram results were available for 43 (74%) cases with 22 reported as abnormal. Age, sex, interval to symptom onset, and vaccines received were similar between KD cases and non-cases. No safety signals were detected in these data.

Idioma original	English
Número de artículo	2088215
Publicación	Human Vaccines and Immunotherapeutics
DOI	https://doi.org/10.1080/21645515.2022.2088215
Estado	Accepted/In press - 2022

Nota bibliográfica

Funding Information:
KAT has received grants from GlaxoSmithKline outside the submitted work. SAH has received grants and consulting fees from Pfizer and GlaxoSmithKline outside the submitted work. MS is supported via salary awards from the BC Children’s Hospital Foundation, the Canadian Child Health Clinician Scientist Program and the Michael Smith Foundation for Health Research. MS has been an investigator on projects funded by GlaxoSmithKline, Merck, Pfizer, Sanofi-Pasteur, Seqirus, Symvivo and VBI Vaccines. All funds have been paid to his institute, and he has not received any personal payments. NKV has recently received stipend from a Pfizer grant outside the submitted work. The other authors have no disclosures.

Publisher Copyright:
© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.

ASJC Scopus Subject Areas

Immunology and Allergy
Immunology
Pharmacology

PubMed: MeSH publication types

Journal Article
Research Support, Non-U.S. Gov't

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.1080/21645515.2022.2088215

Otros archivos y enlaces

Citar esto

Alsager, K., Khatri Vadlamudi, N., Jadavji, T., Bettinger, J. A., Constantinescu, C., Vaudry, W., Tan, B., Sauvé, L., Sadarangani, M., Halperin, S. A., & Top, K. A. (Aceptado/En prensa). Kawasaki disease following immunization reported to the Canadian Immunization Monitoring Program ACTive (IMPACT) from 2013 to 2018. Human Vaccines and Immunotherapeutics, Artículo 2088215. https://doi.org/10.1080/21645515.2022.2088215

Alsager, K, Khatri Vadlamudi, N, Jadavji, T, Bettinger, JA, Constantinescu, C, Vaudry, W, Tan, B, Sauvé, L, Sadarangani, M, Halperin, SA & Top, KA 2022, 'Kawasaki disease following immunization reported to the Canadian Immunization Monitoring Program ACTive (IMPACT) from 2013 to 2018', Human Vaccines and Immunotherapeutics. https://doi.org/10.1080/21645515.2022.2088215

@article{1bedcff0c18247fbae0eb85e7c72c465,

title = "Kawasaki disease following immunization reported to the Canadian Immunization Monitoring Program ACTive (IMPACT) from 2013 to 2018",

abstract = "Kawasaki disease (KD) is an acute systemic vasculitis primarily affecting children younger than 5 y of age that has been reported as an adverse event following immunization (AEFI). The Canadian Immunization Monitoring Program ACTive (IMPACT) conducts active surveillance for KD following immunization across Canada. We characterized KD cases reported to IMPACT between 2013 and 2018. Cases admitted to an IMPACT hospital with a physician diagnosis of complete or incomplete KD with onset 0–42 d following vaccination were reviewed. Cases meeting the Brighton Collaboration case definition (BCCD) levels of diagnostic certainty levels 1 a/b, 2a/b or 3a-e were defined as KD cases. Demographic and vaccination characteristics were compared between KD cases and non-cases. Of 84 cases reviewed, 58 met the BCCD: 47 (81%) cases met level 1a (Complete KD), 8 (14%) met level 1b (Incomplete KD), 2 (3%) met level 2a, and 1 (2%) met level 2c (Probable KD). Median age at admission was 13 months (interquartile range 7–26 months). A median of 9.5 cases were reported per year (range 4–14). Thirty-one (53%) KD cases were temporally associated with diphtheria-tetanus acellular pertussis containing vaccinations, followed by 21 (36%) cases with pneumococcal conjugate vaccines. Symptom onset was 0–14 d after vaccination in 32 (55%) cases. Echocardiogram results were available for 43 (74%) cases with 22 reported as abnormal. Age, sex, interval to symptom onset, and vaccines received were similar between KD cases and non-cases. No safety signals were detected in these data.",

author = "Khaled Alsager and {Khatri Vadlamudi}, Nirma and Taj Jadavji and Bettinger, {Julie A.} and Cora Constantinescu and Wendry Vaudry and Ben Tan and Laura Sauv{\'e} and Manish Sadarangani and Halperin, {Scott A.} and Top, {Karina A.}",

note = "Funding Information: KAT has received grants from GlaxoSmithKline outside the submitted work. SAH has received grants and consulting fees from Pfizer and GlaxoSmithKline outside the submitted work. MS is supported via salary awards from the BC Children{\textquoteright}s Hospital Foundation, the Canadian Child Health Clinician Scientist Program and the Michael Smith Foundation for Health Research. MS has been an investigator on projects funded by GlaxoSmithKline, Merck, Pfizer, Sanofi-Pasteur, Seqirus, Symvivo and VBI Vaccines. All funds have been paid to his institute, and he has not received any personal payments. NKV has recently received stipend from a Pfizer grant outside the submitted work. The other authors have no disclosures. Publisher Copyright: {\textcopyright} 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.",

year = "2022",

doi = "10.1080/21645515.2022.2088215",

language = "English",

journal = "Human Vaccines and Immunotherapeutics",

issn = "2164-5515",

publisher = "Landes Bioscience",

}

TY - JOUR

T1 - Kawasaki disease following immunization reported to the Canadian Immunization Monitoring Program ACTive (IMPACT) from 2013 to 2018

AU - Alsager, Khaled

AU - Khatri Vadlamudi, Nirma

AU - Jadavji, Taj

AU - Bettinger, Julie A.

AU - Constantinescu, Cora

AU - Vaudry, Wendry

AU - Tan, Ben

AU - Sauvé, Laura

AU - Sadarangani, Manish

AU - Halperin, Scott A.

AU - Top, Karina A.

N1 - Funding Information: KAT has received grants from GlaxoSmithKline outside the submitted work. SAH has received grants and consulting fees from Pfizer and GlaxoSmithKline outside the submitted work. MS is supported via salary awards from the BC Children’s Hospital Foundation, the Canadian Child Health Clinician Scientist Program and the Michael Smith Foundation for Health Research. MS has been an investigator on projects funded by GlaxoSmithKline, Merck, Pfizer, Sanofi-Pasteur, Seqirus, Symvivo and VBI Vaccines. All funds have been paid to his institute, and he has not received any personal payments. NKV has recently received stipend from a Pfizer grant outside the submitted work. The other authors have no disclosures. Publisher Copyright: © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.

PY - 2022

Y1 - 2022

N2 - Kawasaki disease (KD) is an acute systemic vasculitis primarily affecting children younger than 5 y of age that has been reported as an adverse event following immunization (AEFI). The Canadian Immunization Monitoring Program ACTive (IMPACT) conducts active surveillance for KD following immunization across Canada. We characterized KD cases reported to IMPACT between 2013 and 2018. Cases admitted to an IMPACT hospital with a physician diagnosis of complete or incomplete KD with onset 0–42 d following vaccination were reviewed. Cases meeting the Brighton Collaboration case definition (BCCD) levels of diagnostic certainty levels 1 a/b, 2a/b or 3a-e were defined as KD cases. Demographic and vaccination characteristics were compared between KD cases and non-cases. Of 84 cases reviewed, 58 met the BCCD: 47 (81%) cases met level 1a (Complete KD), 8 (14%) met level 1b (Incomplete KD), 2 (3%) met level 2a, and 1 (2%) met level 2c (Probable KD). Median age at admission was 13 months (interquartile range 7–26 months). A median of 9.5 cases were reported per year (range 4–14). Thirty-one (53%) KD cases were temporally associated with diphtheria-tetanus acellular pertussis containing vaccinations, followed by 21 (36%) cases with pneumococcal conjugate vaccines. Symptom onset was 0–14 d after vaccination in 32 (55%) cases. Echocardiogram results were available for 43 (74%) cases with 22 reported as abnormal. Age, sex, interval to symptom onset, and vaccines received were similar between KD cases and non-cases. No safety signals were detected in these data.

AB - Kawasaki disease (KD) is an acute systemic vasculitis primarily affecting children younger than 5 y of age that has been reported as an adverse event following immunization (AEFI). The Canadian Immunization Monitoring Program ACTive (IMPACT) conducts active surveillance for KD following immunization across Canada. We characterized KD cases reported to IMPACT between 2013 and 2018. Cases admitted to an IMPACT hospital with a physician diagnosis of complete or incomplete KD with onset 0–42 d following vaccination were reviewed. Cases meeting the Brighton Collaboration case definition (BCCD) levels of diagnostic certainty levels 1 a/b, 2a/b or 3a-e were defined as KD cases. Demographic and vaccination characteristics were compared between KD cases and non-cases. Of 84 cases reviewed, 58 met the BCCD: 47 (81%) cases met level 1a (Complete KD), 8 (14%) met level 1b (Incomplete KD), 2 (3%) met level 2a, and 1 (2%) met level 2c (Probable KD). Median age at admission was 13 months (interquartile range 7–26 months). A median of 9.5 cases were reported per year (range 4–14). Thirty-one (53%) KD cases were temporally associated with diphtheria-tetanus acellular pertussis containing vaccinations, followed by 21 (36%) cases with pneumococcal conjugate vaccines. Symptom onset was 0–14 d after vaccination in 32 (55%) cases. Echocardiogram results were available for 43 (74%) cases with 22 reported as abnormal. Age, sex, interval to symptom onset, and vaccines received were similar between KD cases and non-cases. No safety signals were detected in these data.

UR - http://www.scopus.com/inward/record.url?scp=85133608333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85133608333&partnerID=8YFLogxK

U2 - 10.1080/21645515.2022.2088215

DO - 10.1080/21645515.2022.2088215

M3 - Article

C2 - 35797728

AN - SCOPUS:85133608333

SN - 2164-5515

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

M1 - 2088215

ER -

Kawasaki disease following immunization reported to the Canadian Immunization Monitoring Program ACTive (IMPACT) from 2013 to 2018

Resumen

Nota bibliográfica

ASJC Scopus Subject Areas

PubMed: MeSH publication types

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto